Vertical integration in the Bulgarian pharmaceutical industry is driven by transaction costs, particularly asset specificity. Companies in this sector are growing larger due to the unique attributes of their products and assets. The high transaction costs in Bulgaria lead to more operations being internalized within firms rather than outsourced to the market.